QUEST DIAGNOSTICS INC (DGX)

Quest Diagnostics is a leading U.S.-based diagnostic information services company that generated $11.0 billion in net revenues in 2025, providing laboratory testing insights to physicians, hospitals, patients, health plans, employers, government agencies and pharmaceutical companies. Incorporated in Delaware in 1990 with predecessor operations dating to 1967, the company is headquartered in Secaucus, New Jersey and operates through a network of laboratories, approximately 2,400 patient service centers, and roughly 8,000 total patient access points across the United States, serving about one-third of the U.S. adult population annually and roughly half of U.S. physicians and hospitals. The business consists of two segments: Diagnostic Information Services, which delivers routine, non-routine, and Advanced Diagnostics™ testing (including molecular diagnostics, oncology, neurology, companion diagnostics, and prenatal/genetic testing), and Diagnostic Solutions, which includes risk-assessment services for insurers and healthcare IT offerings under brands such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.

Quest serves hospitals through reference testing (~$1.2 billion in 2025 revenue), Collaborative Lab Solutions lab-management services (~$800 million in revenue and fees), outreach lab acquisitions, and joint ventures such as its 51%-owned venture with Corewell Health in Michigan. For patients and consumers, Quest emphasizes convenience and digital engagement through its MyQuest® portal (45 million+ registered users), QuestHealth.com consumer-initiated testing platform, mobile phlebotomy, self-collection options, and retail-located service centers. The company maintains extensive logistics (over 83,000 daily stops, ~5,000 courier vehicles, 18 aircraft), a large medical and scientific staff (~900 M.D.s/Ph.D.s, ~25,000 phlebotomists and health professionals), and one of the largest de-identifiable clinical lab databases (over 80 billion data points), supporting connectivity with roughly 612,000 clinician/hospital accounts and access to over 90% of U.S. insured lives.

Growth strategy centers on expanding Advanced Diagnostics™ offerings (which generated over $1 billion in revenue in five clinical areas in 2025), strategic acquisitions (targeting 1-2% annual revenue growth), and operational efficiency initiatives including the Invigorate cost-savings program and "Project Nova," a multi-year IT modernization effort with Epic expected to complete by 2031-2032. The company is investing in AI and automation across its value chain, including a 2025 collaboration with Google Cloud, while maintaining an AI governance framework. Notable innovation efforts include the Haystack Oncology minimal-residual-disease test (acquired 2023, granted FDA Breakthrough Device Designation in 2025), the QUEST AD-Detect® Alzheimer's risk testing portfolio, and the Autoimmune ANAlyzeR™ screening service.

Quest also maintains a capital allocation framework combining acquisitions, dividends (increased to $0.86 per share in February 2026, its 15th increase since 2012), share repurchases (~$8.1 billion since 2012), and continued investment in quality programs, community health initiatives (~$53 million invested), and global diagnostics collaboration through the Global Diagnostics Network.